Table 2.
Pathway | Stomach | Duodenum | Jejunum | Ileum | A.colon | D.colon |
---|---|---|---|---|---|---|
(A) Pathways over‐represented in up‐regulated genes | ||||||
Blood coagulation | 15* | 0 | 0 | 0 | 0 | 0 |
Bile acids regulation of glucose and lipid metabolism via FXR | 10* | 0 | 0 | 3# | 0 | 0 |
Glycine, serine, cysteine and threonine metabolism | 10* | 0 | 0 | 0 | 0 | 0 |
Linoleic acid | 6* | 0 | 0 | 0 | 0 | 0 |
FXR‐dependent negative‐feedback regulation of bile acids concentration | 6* | 0 | 0 | 0 | 0 | 0 |
Platelet microparticle generation | 14* | 0 | 0 | 0 | 0 | 0 |
Phenylalanine metabolism | 7* | 0 | 0 | 0 | 0 | 0 |
PXR sigling via cross‐talk | 6* | 0 | 0 | 2# | 0 | 0 |
Propiote metabolism p.1 | 5* | 0 | 0 | 0 | 0 | 0 |
Leucine, isoleucine and valine metabolism.p.2 | 7* | 0 | 0 | 0 | 0 | 0 |
Tight junctions | 11* | 0 | 0 | 0 | 0 | 0 |
(L)‐Alanine, (L)‐cysteine, and (L)‐methionine metabolism | 6* | 0 | 0 | 0 | 0 | 0 |
Sulfur metabolism | 6* | 0 | 0 | 0 | 0 | 0 |
FXR‐regulated cholesterol and bile acids cellular transport | 6* | 0 | 0 | 0 | 0 | 0 |
Triacylglycerol metabolism p.2 | 3# | 3* | 0 | 0 | 0 | 0 |
Glycolysis and gluconeogenesis p.1 | 0 | 0 | 0 | 4* | 0 | 0 |
Fructose metabolism | 5# | 0 | 0 | 4* | 0 | 0 |
GnRH sigling | 0 | 0 | 0 | 6* | 0 | 0 |
Aldosterone‐mediated regulation of EC sodium transport | 0 | 0 | 0 | 2# | 2# | 3* |
Impaired NO sigling in CF airways | 0 | 0 | 0 | 0 | 0 | 2* |
(B) Pathways over‐represented in down‐regulated genes | ||||||
Huntingtin‐depended transcription deregulation in Huntington's Disease | 5* | 0 | 0 | 0 | 0 | 0 |
Antigen presentation by MHC class II | 4* | 0 | 0 | 0 | 0 | 0 |
IFN alpha/beta sigling pathway | 0 | 0 | 0 | 0 | 0 | 4* |
Antiviral actions of Interferons | 4# | 0 | 0 | 0 | 0 | 4* |
IFN gamma sigling pathway | 0 | 0 | 0 | 0 | 0 | 3 |
*indicates FDR < 0.1 and # P‐value < 0.05 for the significance of the pathway in the specified tissue.